98 related articles for article (PubMed ID: 38754043)
1. Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?
Stetson D; Labrousse P; Russell H; Shera D; Abbosh C; Dougherty B; Barrett JC; Hodgson D; Hadfield J
J Clin Oncol; 2024 May; ():JCO2302301. PubMed ID: 38754043
[No Abstract] [Full Text] [Related]
2. "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.
Pacelli P; Raspadori D; Bestoso E; Gozzetti A; Bocchia M
Front Oncol; 2022; 12():1057713. PubMed ID: 36518304
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
5. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Circulating molecular biomarkers: next-generation tools for monitoring minimal residual disease in cancer patients.
Amoozgar Z; Jaymand M; Jahanban-Esfahlan R
Front Oncol; 2023; 13():1226974. PubMed ID: 37554172
[No Abstract] [Full Text] [Related]
8. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
9. Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing.
Sperotto A; Bochicchio MT; Simonetti G; Buccisano F; Peccatori J; Piemontese S; Calistri E; Ciotti G; Pierdomenico E; De Marchi R; Ciceri F; Gottardi M
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830896
[TBL] [Abstract][Full Text] [Related]
10. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies.
Dogliotti I; Drandi D; Genuardi E; Ferrero S
J Clin Med; 2018 Sep; 7(9):. PubMed ID: 30231510
[TBL] [Abstract][Full Text] [Related]
11. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.
Vonk CM; Al Hinai ASA; Hanekamp D; Valk PJM
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771594
[TBL] [Abstract][Full Text] [Related]
12. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
13. Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
Balduzzi A
Bone Marrow Transplant; 2017 Jul; 52(7):952-954. PubMed ID: 28581473
[No Abstract] [Full Text] [Related]
14. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
15. Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA.
Rausch C; Rothenberg-Thurley M; Buerger SA; Tschuri S; Dufour A; Neusser M; Schneider S; Spiekermann K; Metzeler KH; Ziemann F
J Mol Diagn; 2021 Aug; 23(8):975-985. PubMed ID: 34020042
[TBL] [Abstract][Full Text] [Related]
16. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
Ravandi F; Jorgensen JL
J Natl Compr Canc Netw; 2012 Aug; 10(8):1029-36. PubMed ID: 22878826
[TBL] [Abstract][Full Text] [Related]
19. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.
Gozzetti A; Raspadori D; Bacchiarri F; Sicuranza A; Pacelli P; Ferrigno I; Tocci D; Bocchia M
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32927719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
